Apollomics Inc. (NASDAQ:APLM – Get Free Report) shares passed below its two hundred day moving average during trading on Wednesday. The stock has a two hundred day moving average of $19.01 and traded as low as $19.00. Apollomics shares last traded at $18.72, with a volume of 45,700 shares changing hands.
Analyst Upgrades and Downgrades
A number of analysts have commented on the company. Wall Street Zen upgraded Apollomics to a “hold” rating in a research report on Saturday, August 22nd. Weiss Ratings upgraded Apollomics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock presently has an average rating of “Sell”.
Get Our Latest Research Report on Apollomics
Apollomics Stock Performance
The business’s 50 day simple moving average is $23.00 and its 200 day simple moving average is $19.01.
Insider Activity
In other news, CFO Peter Lin bought 26,667 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was acquired at an average price of $15.00 per share, for a total transaction of $400,005.00. Following the transaction, the chief financial officer directly owned 48,979 shares of the company’s stock, valued at $734,685. This trade represents a 119.52% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Hung-Wen Chen purchased 266,667 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The shares were purchased at an average cost of $15.00 per share, with a total value of $4,000,005.00. Following the completion of the acquisition, the chief executive officer directly owned 1,029,695 shares in the company, valued at $15,445,425. The trade was a 34.95% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have bought 583,334 shares of company stock worth $8,250,510.
Hedge Funds Weigh In On Apollomics
A hedge fund recently bought a new position in Apollomics stock. Citadel Advisors LLC acquired a new position in shares of Apollomics Inc. (NASDAQ:APLM – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,664 shares of the company’s stock, valued at approximately $224,000. Citadel Advisors LLC owned about 0.48% of Apollomics at the end of the most recent quarter. 19.13% of the stock is owned by hedge funds and other institutional investors.
About Apollomics
Apollomics, Inc (NASDAQ:APLM) is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of cancer. Its research programs are centered on immuno-oncology and precision oncology, with the goal of combining therapies that activate the immune system with treatments designed to target specific characteristics of tumors.
The company’s pipeline includes investigational small-molecule and antibody-based therapies intended for use across a range of solid tumors and blood cancers.
Recommended Stories
- Five stocks we like better than Apollomics
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Apollomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollomics and related companies with MarketBeat.com's FREE daily email newsletter.
